With the development of molecular targeted therapy and immunotherapy, patients with intermediate and advanced lung cancer who are positive for driver genes or have high PD-L1 expression can further benefit from targeted therapy or immunotherapy. The gene discussed is CD274; the disease is lung carcinoma.